HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on cardiac care, has announced a commercial agreement with Atelier Health, a Beverly Hills-based concierge medical practice. This partnership expands HeartBeam’s launch footprint into Southern California, completing its initial targeted markets alongside the New York metro area, Dallas, and South Florida as the company advances commercialization of its cable-free 3D ECG technology for remote cardiac monitoring and preventive cardiology.
The agreement marks a significant step for HeartBeam as it seeks to bring its innovative 3D ECG technology to a broader patient population. The technology, which received FDA clearance for arrhythmia assessment in December 2024 and for 12-lead ECG synthesis software in December 2025, is designed to collect ECG signals from three non-coplanar directions and synthesize them into a standard 12-lead ECG. This cable-free device is intended for use outside of medical facilities, allowing physicians to identify cardiac health trends and acute conditions and direct patients to appropriate care remotely.
For the concierge cardiology sector, the partnership with HeartBeam provides an opportunity to offer cutting-edge remote monitoring capabilities to their patients. Concierge practices like Atelier Health focus on personalized, accessible care, and integrating HeartBeam’s technology aligns with their model of providing high-touch, preventive health services. The technology enables continuous cardiac monitoring without the need for patients to visit a clinic, potentially improving early detection of arrhythmias and other cardiac issues.
The expansion into Southern California is strategically important as the region has a high concentration of affluent patients who often seek concierge medical services. By partnering with Atelier Health, HeartBeam gains a foothold in this market, which could serve as a springboard for further adoption among other concierge practices and healthcare providers. The company already has a presence in other key markets, and this agreement completes its initial targeted footprint.
HeartBeam holds over 20 issued patents related to its technology, underscoring its commitment to innovation in cardiac care. The company’s platform is designed to deliver actionable heart intelligence, enabling physicians to make informed decisions based on continuous data. As the healthcare industry increasingly shifts toward remote monitoring and telehealth, HeartBeam’s technology addresses a growing need for convenient, reliable cardiac assessment tools.
For more information on HeartBeam’s cleared indications for use, visit https://www.heartbeam.com/indications. The latest news and updates on BEAT are available in the company’s newsroom at https://ibn.fm/BEAT.
